Everest Organics Ltd

₹

- close price

About

Everest Organics Ltd (EOL) makes active pharmaceutical ingredients (APIs), the main medicinal ingredients in finished medicines,
and chemical intermediates used to make APIs. Its factory is at Aroor, Sangareddy, Telangana.^[1]

Key Points

Product Profile:
a) APIs:^[1]
Company has products for Gastroenterology, Hypercholesterolemia, Benign Prostatic, Anti Convulsant, Hypertrophy, Hyperuricemia
and Gout, Anti Thrombotic, Anti Fungal,
Anti Viral, Anti Emetics, Anti Diabetic,
Insomnia, Skeletal muscle relaxant,
Overactive Bladder, Rhino-Conjunctivitis,
etc.
b) Intermediates:^[2]
Febuxostat, Ilaprazole, Imatinib, Oseltamivir Phosphate, Abiraterone Acetate, Rivaroxaban, Itraconazole, Omeprazole, Pantoprazole, Rabeprazole, Esomeprazole, Pemetrexed, Pregabalin, Hydroxy, Chloro compound,
Sulphide, Pyrazine, Gancyclovir, Apixaban, Aprepitant, Bilastine, etc.
c) By Products:^[2]
Ammonium Sulphate, Sodium Nitrite, Di
Sodium Orthophosphate, Di Ammonium
Phosphate

Website BSE

Market Cap ₹ Cr.
Current Price ₹
High / Low ₹ /
Stock P/E
Book Value ₹
Dividend Yield %
ROCE %
ROE %
Face Value ₹

Add ratio to table

Edit ratios

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores




Operating Profit
OPM %

Interest
Depreciation
Profit before tax
Tax %

EPS in Rs
Raw PDF

Profit & Loss

Figures in Rs. Crores




Operating Profit
OPM %

Interest
Depreciation
Profit before tax
Tax %

EPS in Rs
Dividend Payout %

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	%

Balance Sheet

Figures in Rs. Crores


Equity Capital
Reserves


Total Liabilities

CWIP
Investments

Total Assets

Cash Flows

Figures in Rs. Crores





Net Cash Flow
Free Cash Flow
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit

Ratios


Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Capacity Utilization - Benzimidazole
% ・Standalone data

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xxx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xxx.xx	xxx.xx	xxx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xxx.xx	xx.xx	xx.xx	xx.xx	xxx.xx
xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx		xx.xx	xx.xx	xx.xx	xx.xx
					xx	xx	xx	xx		xx	xx
					xx	xx	xx	xx		xx	xx

Please log in to see hidden values.

Capacity Utilization - Esomeprazole
% ・Standalone data

Production Volume - Benzimidazole
MT ・Standalone data

Production Volume - Esomeprazole Magnesium
MT ・Standalone data

Production Volume - Omeprazole Powder
MT ・Standalone data

Capacity Utilization - Omeprazole
% ・Standalone data

Number of Clients
count ・Standalone data

Number of Countries Served
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
	74.15%	74.15%	74.15%	74.15%	74.15%	61.09%	60.99%	59.64%	59.61%	59.58%	59.60%	60.62%
	0.03%	0.03%	0.03%	0.05%	0.05%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%
	25.82%	25.83%	25.83%	25.81%	25.80%	38.90%	38.99%	40.35%	40.36%	40.40%	40.38%	39.36%
No. of Shareholders	10,242	10,023	9,792	9,996	9,326	8,756	8,281	8,079	7,804	7,880	7,827	7,792

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Sep 2026
	72.82%	73.18%	73.27%	73.79%	74.15%	74.15%	74.15%	74.15%	61.09%	59.58%	60.62%
	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%	0.02%	0.02%	0.02%
	27.15%	26.79%	26.71%	26.19%	25.82%	25.82%	25.83%	25.83%	38.90%	40.40%	39.36%
No. of Shareholders	7,878	7,567	7,431	7,110	8,122	11,154	10,834	10,023	8,756	7,880	7,792

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Everest Organics Ltd

Everest Organics Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls